Plural C=o Groups, Other Than As Ketone Or Aldehyde Patents (Class 514/121)
  • Patent number: 9758536
    Abstract: The present invention concerns phospholipid compositions having a relatively high concentration of compounds of the following structure (I): wherein at least one of R1 and R2 is palmitoleoyl, myristoleoyl or lauroleoyl and methods for their preparation. The present invention also concerns the use of these phospholipid compositions to treat a variety of disorders by administering the composition to a patient in need thereof.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: September 12, 2017
    Assignee: Omega Protein Corporation
    Inventors: Ernesto Hernandez, Marina Rusli, Mark Griffin
  • Patent number: 9062052
    Abstract: Disclosed are carboxamide compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure in which R1, R2, R3, R4, D, J, Z, T, p, q, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: June 23, 2015
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Jiaxin Yu, Hui Hong, Ihab S. Darwish, Xiang Xu, Rajinder Singh
  • Publication number: 20150148316
    Abstract: The subject invention includes a composition comprising at least one triglyceride, at least one phospholipid and at least one poly-unsaturated fatty acids (LC-PUFA); wherein at least about 1% of the LC-PUFA in the composition is conjugated to said phospholipid and uses thereof.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 28, 2015
    Inventors: FABIANA BAR YOSEF, DORI PELLED, ARIEL KATZ
  • Publication number: 20150119368
    Abstract: A composition and a method of treatment for the reduction of risk factors for cardiovascular disease utilizing a combination of lipid lowering cholesterol absorption inhibitors, e.g. azetidinones, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.
    Type: Application
    Filed: January 2, 2015
    Publication date: April 30, 2015
    Applicant: PIVOTAL THERAPEUTICS INC.
    Inventors: George JACKOWSKI, Rachelle MACSWEENEY, Nisar Ahmad SHAIKH, Jason YANTHA, Valerie B. SCHINI-KERTH
  • Patent number: 8974803
    Abstract: Injectable biomaterial compositions formed from tropoelastin for tissue repair and restoration. The compositions include a coalescence-controlling agent in the form of a polysaccharide or polysaccharide derivative, in an amount effective for providing the substance with the properties of flow, enabling injection.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: March 10, 2015
    Assignee: The University of Sydney
    Inventors: Anthony Steven Weiss, Suzanne Marie Mithieux
  • Publication number: 20150065461
    Abstract: The present invention relates to vesicular formulations for use in the treatment of pain and/or reduced mobility associated with a loss of lubrication and/or structural integrity and/or swelling of a collagen structure. It also relates to a method of treating pain such as joint pain or tendonitis comprising topically administering a vesicular formulation according to the invention.
    Type: Application
    Filed: April 12, 2013
    Publication date: March 5, 2015
    Inventors: Richard Wolf Garraway, Michael Earl, Saruhan Yurdakul, Nicholas Baverstock
  • Patent number: 8962600
    Abstract: Apocynin derivative compounds, active pharmaceutical ingredients, dosage forms, and methods of use thereof as neuroprotectants in the brain of mammals.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: February 24, 2015
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Balaraman Kalyanaraman, Joy Joseph, Anumantha Kanthasamy
  • Publication number: 20150038469
    Abstract: The present invention provides for methods of preventing or improving cardiometabolic disorders/metabolic disorders, compositions and pharmaceutical compositions comprising therapeutically effective amount of therapeutic phospholipid compositions and therapeutically effective amount of one or more lipid modifying agents, including statins.
    Type: Application
    Filed: March 7, 2014
    Publication date: February 5, 2015
    Applicant: Neptune Technologies & Bioressources, Inc.
    Inventor: Fotini Sampalis
  • Publication number: 20150037404
    Abstract: A method for lubricating a joint of a mammal by administering into a cavity of the joint a composition of liposomes that are multilamellar vesicles (MLV) dispersed in a fluid medium, the liposomes having a mean diameter of between about 0.8 ?m to about 10 ?m and including membranes of at least one glycerophospholipid (GPL) having two C12-C16 hydrocarbon chains which are the same or different. These membranes have a phase transition temperature in which solid ordered (SO) to liquid disordered (LD) phase transition occurs, the phase transition temperature being at a temperature of about 20° C. to about 39° C. and being lower than the temperature of the joint.
    Type: Application
    Filed: October 22, 2014
    Publication date: February 5, 2015
    Applicants: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
    Inventors: Yechezkel BARENHOLZ, Dorit NITZAN, Izhak ETSION, Avi SCHROEDER, Grigory HALPERIN, Sarit SIVAN
  • Publication number: 20150030541
    Abstract: The present invention provides phosphonate conjugates and methods of preparing the phosphonate conjugates so as to allow, for example, improved methods and compounds for modifying the surface of a nanoparticle to increase in vivo circulation times and targeted delivery performance.
    Type: Application
    Filed: October 14, 2014
    Publication date: January 29, 2015
    Inventor: Thomas E. Rogers
  • Patent number: 8921342
    Abstract: Disclosed is a liver function-protecting agent which comprises a phospholipid as an active ingredient, and which can exhibit an excellent prophylactic and ameliorating effect on the deterioration in the liver function when ingested orally. Also disclosed is a liver function-protecting food, beverage or feed. The phospholipid is preferably one derived from milk or a milk material. Alternatively, the phospholipid may be used in the form of a phospholipid-containing composition prepared from milk or a milk material and containing the phospholipid in an amount of 10 wt % or more relative to the total solid content.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: December 30, 2014
    Assignee: Megmilk Snow Brand Co., Ltd.
    Inventors: Tomoyuki Isogai, Yukio Kadooka, Reo Tanaka, Akira Tomizawa
  • Patent number: 8912355
    Abstract: Described herein are compositions of an linoleic phospholipid for inhibiting inflammatory pathways or neurodegenerative processes. Also provided are uses of such compositions and methods of inhibiting inflammatory or neurodegenerative processes by administering a composition that includes an linoleic phospholipid and optionally a carrier to a cell, cell culture or subject in need of such treatment.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: December 16, 2014
    Assignee: University of Ottawa Heart Institute
    Inventors: Nihar Pandey, Daniel Sparks
  • Publication number: 20140364400
    Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
    Type: Application
    Filed: August 22, 2014
    Publication date: December 11, 2014
    Inventor: Annabelle Gallois-Bernos
  • Publication number: 20140364399
    Abstract: The present invention concerns phospholipid compositions having a relatively high concentration of compounds of the following structure (I): wherein at least one of R1 and R2 is palmitoleoyl, myristoleoyl or lauroleoyl and methods for their preparation. The present invention also concerns the use of these phospholipid compositions to treat a variety of disorders by administering the composition to a patient in need thereof.
    Type: Application
    Filed: December 6, 2012
    Publication date: December 11, 2014
    Applicant: OMEGA PROTEIN CORPORATION
    Inventors: Ernesto Hernandez, Marina Rusli, Mark Griffin
  • Publication number: 20140357568
    Abstract: A method of increasing muscle mass and strength in mammals by orally administering a therapeutically effective amount of phosphatidic acid. The phosphatidic acid is preferably administered as a plurality of doses per day with at least one dose being administered during the anabolic window following exercise. Preferably, the method further includes the cotemporaneous administration of a therapeutically effective amount of creatine, optionally as phosphatidylcreatine. In addition or in the alternative, the method further includes the cotemporaneous administration of a therapeutically effective amount of leucine, optionally as phosphatidylleucine.
    Type: Application
    Filed: May 31, 2013
    Publication date: December 4, 2014
    Inventors: Robert Clarke, Matthew Cahill, Brian Sweet
  • Publication number: 20140323442
    Abstract: The present invention provides a small molecule treatment of diseases/conditions caused by a virus carrying a viral oncoprotein. In one embodiment, the virus which carries the viral oncoprotein is HPV. The small molecule useful herein includes thiadiazolin-3,5-dione compounds having an optionally substituted aryl group bound to one nitrogen atom of said thiadiazolin-3,5-dione compound. The small molecules may also be administered with a compound which inhibits binding of HPV E6 to p53. In one embodiment, the thiadiazolin-3,5-dione compound has formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, or metabolite thereof, wherein R1 and R2 are defined herein.
    Type: Application
    Filed: November 6, 2012
    Publication date: October 30, 2014
    Inventors: Ronen Marmorstein, Daniela Fera
  • Publication number: 20140301958
    Abstract: The purpose of this patent is to teach the methods of application and compositions of cosmetic and therapeutic products for reducing wrinkle appearance and augmenting certain compartments of the facial integument of a mammal, especially a human. These methods and compositions utilize the hypodermis-targeted release from bioadhesive oral films, pastes or patches applied to oral mucosa or teeth for the purpose of improving the appearance or health of the lips and facial skin.
    Type: Application
    Filed: April 20, 2012
    Publication date: October 9, 2014
    Inventors: Krzysztof Bojanowski, Hui Zhao
  • Publication number: 20140274922
    Abstract: Provided herein are exemplary algal omega 7 compositions, including algal fatty acid compositions comprising by dry weight from about approximately 0.5% to about approximately 99% C16:1 n7 palmitoleic acid (POA). Such algal compositions may also include (either individually or any combination of) by dry weight: from about approximately 0% to about approximately 20% saturated fatty acids; from about approximately 0% to about approximately 99% arachidonic acid; from about approximately 0% to about 99% docosahexaenoic acid; and/or from about approximately 0% to about approximately 99% eicosapentaenoic acid. Further exemplary algal fatty acid compositions may include by dry weight about approximately 90% POA, less than about approximately 20% saturated fatty acids, less than about approximately 10% ARA, substantially no DHA, and less than about approximately 10% EPA.
    Type: Application
    Filed: September 12, 2013
    Publication date: September 18, 2014
    Applicant: Aurora Algae, Inc.
    Inventors: Leslie van der Meulen, Daniel Fleischer, Michelle L. Collins, James Astwood, Jeffrey Gerard Hippler, Andrew Thompson
  • Patent number: 8802663
    Abstract: The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases, wherein R1, R2 and R3 are as defined in the description.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: August 12, 2014
    Assignee: Merck Serono SA
    Inventors: Anna Quattropani, Charles Baker-Glenn, Wesley Blackaby, Chris Knight
  • Publication number: 20140120171
    Abstract: A method of parenterally administering a composition, the method including parenterally administering to a person a composition including krill oil in an oil-in-water emulsion. A parenterally applicable pharmaceutical composition, including an oil-in-water emulsion including a phospholipid obtained from a marine crustacean.
    Type: Application
    Filed: June 13, 2012
    Publication date: May 1, 2014
    Applicant: STABLE SOLUTIONS LLC
    Inventor: David F. Driscoll
  • Patent number: 8703747
    Abstract: The present invention relates to a compound of the following general formula (I): R1—NH—CH(R2)—P(?O)(OR3)—CH2—C(R4)(R5)—CONH—CH(R6)—COOR7 (I) or a pharmaceutically acceptable salt of the latter, an isomer or a mixture of isomers in any proportions, especially a mixture of enantiomers, and in particular a racemic mixture, for which R1 represents a —C(?O)—O—C(R8)(R9)—OC(?O)—R10 group; R2 represents an optionally substituted hydrocarbon-based chain, an aryl or heteroaryl group or a methylene group substituted by a heterocycle; R3 represents a hydrogen atom or a —C(R12)(R13)—OC(?O)—R14 group; R4 and R5 form, together with the carbon that bears them, a saturated hydrocarbon-based ring or an optionally substituted piperidine ring or R4 represents a hydrogen atom and R5 represents a phenyl or a benzyl that is optionally substituted, a heteroaromatic ring or a methylene group substituted by a heterocycle; R6 represents an optionally substituted hydrocarbon-based chain or a phenyl or a benzyl that is optionally substi
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: April 22, 2014
    Assignee: Pharmaleads
    Inventors: Bernard Roques, Hervé Poras, Marie-Claude Fournie-Zaluski
  • Publication number: 20140107080
    Abstract: Brain function improving agents, cognitive judgment ability improving agents, as well as foods and beverages that contain krill oil as an active ingredient are provided.
    Type: Application
    Filed: May 31, 2012
    Publication date: April 17, 2014
    Applicant: NIPPON SUISAN KAISHA, LTD.
    Inventors: Yoshihiko Koga, Chizuru Konagai, Kenichi Yanagimoto, Kohsuke Hayamizu
  • Patent number: 8697676
    Abstract: A novel omega-3 fatty acid/lipid based nutraceutical composition and a method of optimizing said omega-3 fatty acid/lipid based nutraceutical composition. The nutraceutical composition and method is based on the insight that different forms of high omega-3 fatty acid lipids (e.g. triglyceride form, ethyl ester form, free fatty acid form, phospholipid form) have different molecular modes and levels of action. Specifically the phospholipid form is likely more effective at promoting membrane fluidity and permeability, while the free fatty acid form is likely more effective at regulating cell receptors, such as the PPAR? receptors, that are responsible for various metabolic effects including lipid metabolism. The desirability of producing omega-3 compositions that may act synergistically and thus more robustly to improve health and to some extent mimic markers of life extension such as shown by caloric restriction, along with specific optimization methods, markers, and compositions are taught.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: April 15, 2014
    Inventor: Ronald E Rosedale
  • Publication number: 20130344000
    Abstract: Described herein are methods for the treatment of cognitive impairment in a subject with a neurological autoimmune disease and methods for determining whether a subject who has a central nervous system autoimmune disease is likely to acquire a cognitive impairment.
    Type: Application
    Filed: December 14, 2011
    Publication date: December 26, 2013
    Applicant: The Johns Hopkins University
    Inventors: Adam Kaplin, Barbara S. Slusher, Kristen A. Rahn
  • Publication number: 20130337041
    Abstract: The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of cholesterol and regulate the function of lipolytic enzymes, retard prothrombin formation and aid in the clearance of virus and bacterial particles. Negatively charged lipid compositions can therefore be administered to humans and animals for the treatment of hyperlipidemia and blood coagulation disorders and to reduce the levels of virus, bacteria, and endotoxins in the blood stream. Positively charged lipid compositions can be administered to delay lipoprotein clearance from the plasma compartment and give longer duration of activity for drugs which are associated with lipoproteins.
    Type: Application
    Filed: February 25, 2013
    Publication date: December 19, 2013
    Applicants: Ottawa Heart Institute Research Corporation, Cerenis Therapeutics, S.A.
    Inventors: Cerenis Therapeutics, S.A., Ottawa Heart Institute Research Corporation
  • Publication number: 20130338114
    Abstract: Phosphatidic acid, lyso-phosphatidic acid, and/or phospholipase D can be administered to exercising mammals to increase muscle mass and strength. These actives can be administered orally to aging, bedridden or cachectic patients, as well as resistance training individuals, to improve nitrogen balance. The oral administration of phosphatidic acid as well as other actives described herein was found to increase muscle hypertrophy, strength, and lean body mass, and to decrease body fat in subjects, for example, when combined with resistance training.
    Type: Application
    Filed: May 23, 2013
    Publication date: December 19, 2013
    Applicant: Chemi Nutra
    Inventors: Lorenzo DE FERRA, Marvin A. HEUER, Scott L. HAGERMAN, Martin PURPURA, Ralf JAEGER
  • Patent number: 8609142
    Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: December 17, 2013
    Assignee: BIND Therapeutics, Inc.
    Inventors: Greg Troiano, Michael Figa, Abhimanyu Sabnis
  • Patent number: 8598084
    Abstract: An herbicide/insecticide composition containing (a) a pyridine carboxylic acid component and (b) an insecticide component provides synergistic control of selected weeds.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: December 3, 2013
    Assignee: Dow AgroSciences, LLC.
    Inventors: Norbert M. Satchivi, Paul R. Schmitzer
  • Publication number: 20130303466
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
    Type: Application
    Filed: October 18, 2011
    Publication date: November 14, 2013
    Applicant: ELCELYX THERAPEUTICS, INC.
    Inventors: Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley, Alain D. Baron
  • Publication number: 20130287749
    Abstract: The present invention relates to novel phosphonic acid formulations and to their use as slug and snail baits, and to the corresponding slug and snail baits, to a process for their preparation and to their use for controlling slugs and snails.
    Type: Application
    Filed: September 30, 2011
    Publication date: October 31, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Wolfgang Wirth, Margit Doth, Sybille Lamprecht, Hubert Schmeer
  • Publication number: 20130281409
    Abstract: Methods are provided for decreasing inflammatory disease in a subject by administering an effective dose of a lipid, fatty acid, or analog thereof.
    Type: Application
    Filed: March 19, 2013
    Publication date: October 24, 2013
    Inventors: The Board of Trustees of the Leland Stanford Junior University, Department of Veterans Affairs
  • Patent number: 8524692
    Abstract: The present invention provides a method of treating a corneal disorder comprising administering to a patient in need thereof a composition containing pharmaceutically effective amount of dioleoylphosphatidylglycerol and/or palmitoyloleoylphosphatidylglycerol and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: September 3, 2013
    Assignee: Georgia Health Sciences University Research Institute, Inc.
    Inventors: Wendy Bollag, Ding Xie
  • Publication number: 20130217654
    Abstract: The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions.
    Type: Application
    Filed: January 2, 2013
    Publication date: August 22, 2013
    Applicant: NATIONAL JEWISH HEALTH
    Inventor: National Jewish Health
  • Publication number: 20130202689
    Abstract: A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.
    Type: Application
    Filed: January 25, 2013
    Publication date: August 8, 2013
    Applicant: NEPTUNE TECHNOLOGIES & BIORESSOURCES, INC.
    Inventor: NEPTUNE TECHNOLOGIES & BIORESSOURCES, Inc.
  • Publication number: 20130079310
    Abstract: A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.
    Type: Application
    Filed: August 13, 2012
    Publication date: March 28, 2013
    Applicant: PIVOTAL THERAPEUTICS INC.
    Inventors: George JACKOWSKI, Rachelle MACSWEENEY, Nisar SHAIKH, Jason YANTHA, Valerie SCHINI-KERTH
  • Publication number: 20130059768
    Abstract: The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like.
    Type: Application
    Filed: August 31, 2012
    Publication date: March 7, 2013
    Applicant: ARCTIC NUTRITION AS
    Inventors: Hogne HALLARAKER, Jan REMMEREIT, Alvin BERGER
  • Publication number: 20130034535
    Abstract: Combinations of one or more anti-obesity drugs with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight comprised of a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA comprise about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics.
    Type: Application
    Filed: August 13, 2012
    Publication date: February 7, 2013
    Applicant: PIVOTAL THERAPEUTICS INC.
    Inventors: George JACKOWSKI, Rachelle MACSWEENEY, Nisar SHAIKH, Jason YANTHA, Valerie SCHINI-KERTH
  • Publication number: 20130004439
    Abstract: The compound according to the invention has the following developed formula IX: wherein: X=PO(OH)2; SO2(OH); PO(OH)(Xaa)m or SO2(Xaa)m; A=H; OH; NH2 or akyl (1-6C); n=1 to 4; Y=—CO—OR2; —CO—NR3R4; —O—CO—R2; —C?CR2; R2=an alkyl, aryl, aralkyl, acyl, sulfonyl, sugar or alkoxy chain of 1 to 24 carbon atoms, linear, branched or cyclic, with or without substitutions, saturated or not, hydroxylated or not, sulfurated or not; R5=OH, O-alk (1-6C), (Xaa)m, NH2 or NH-alkyl(1-6C); Xaa=peptide of m aminoacids Xaa with m from 1 to 10; The compound is preferably phosphated, obtained from malic acid and having the following developed formula: A cosmetic composition comprising the compound of the present invention can improve the general condition of the skin, for example hydration, lightening and mechanical properties.
    Type: Application
    Filed: January 17, 2011
    Publication date: January 3, 2013
    Applicant: Sederma, S.A.S.
    Inventors: Arnaud Fournial, Philippe Mondon, Olivier Peschard
  • Publication number: 20120328518
    Abstract: This invention relates to novel compounds suitable for labelling by 18F and the corresponding 18F labelled compounds themselves, 19F-fluorinated analogues thereof and their use as reference standards, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).
    Type: Application
    Filed: December 16, 2010
    Publication date: December 27, 2012
    Applicant: PIRAMAL IMAGING SA
    Inventors: Keith Graham, Georg Kettschau, Ralf Lesche, Alexey Gromov, Niels Bohnke, Jorma Hassfeld
  • Publication number: 20120321720
    Abstract: A method of parenterally administering a composition, the method including parenterally administering to a person a composition including krill oil in an oil-in-water emulsion. A parenterally applicable pharmaceutical composition, including an oil-in-water emulsion including a phospholipid obtained from a marine crustacean.
    Type: Application
    Filed: June 15, 2011
    Publication date: December 20, 2012
    Inventor: David F. DRISCOLL
  • Publication number: 20120316139
    Abstract: Compounds of the general formula are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also disclosed.
    Type: Application
    Filed: July 27, 2012
    Publication date: December 13, 2012
    Inventor: Basil RIGAS
  • Publication number: 20120288568
    Abstract: Compounds that reduce serum retinol, serum RBP, and/or serum retinol-RBP levels may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.
    Type: Application
    Filed: May 17, 2012
    Publication date: November 15, 2012
    Applicant: Revision Therapeutics, Inc.
    Inventors: Kenneth Widder, Jay Lichter, Nathan L. Mata
  • Publication number: 20120277196
    Abstract: A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.
    Type: Application
    Filed: July 10, 2012
    Publication date: November 1, 2012
    Applicant: NEPTUNE TECHNOLOGIES & BIORESSOURCES, INC.
    Inventor: Fotini Sampalis
  • Publication number: 20120263698
    Abstract: A method for reducing alpha-synuclein amyloid protein in a patient suffering from Parkinson's Disease comprising administering to the patient an effective amount of trans-resveratrol, a method for treating a neurodegenerative disease associated with amyloid proteins comprising administering to a patient in need thereof an effective amount of trans-resveratrol, and a method for treating Parkinson's Disease comprising administering to a patient in need thereof a pharmaceutically effective amount of carbidopa, levodopa, and trans-resveratrol are described. More particularly, the effect of trans-resveratrol on reducing the pharmaceutically effective dose of at least one of carbidopa and levodopa in the treatment of Parkinson's Disease is described. In addition, a method of improving cognition, speech and/or movement in a patient suffering from Parkinson's Disease comprising administering to the patient carbidopa, levodopa and trans-resveratrol is described.
    Type: Application
    Filed: April 20, 2012
    Publication date: October 18, 2012
    Inventor: Elizabeth K. Barber
  • Publication number: 20120238521
    Abstract: The invention is directed to a composition and associated method for the treatment of musculoskeletal related disorders and diseases. In particular, the present invention provides a class of citrate compounds that can be used to for the treatment of diseases/disorders characterized by the degeneration of musculoskeletal tissues including menisci, bone, articular cartilage, and soft tissues. Examples of suitable citrate and citrate analog compounds include citrates having the following base formula (I): where X may be one of the following: wherein Y, Y?, and Y? are independently a citrate moiety, O, O—Y, OH, NH, NH—Y, R and R—Y, with R being an alkyl, alkyene, ester, aryl, or phenyl group having from 1 to 6 carbon atoms.
    Type: Application
    Filed: March 12, 2012
    Publication date: September 20, 2012
    Applicant: The Charlotte-Mecklenbury Hospital Authority d/b/a Carolinas Medical Center
    Inventors: Yubo Sun, Edward N. Hanley
  • Publication number: 20120225114
    Abstract: The present invention provides compositions and methods for modulating one or more phenotypes of a macrophage-related cell, e.g., a macrophage. The invention further provides methods of treating disease by modulating macrophage phenotype. Representative phenotypes include pro-inflammatory, anti-inflammatory, immunogenic, tolerogenic, tissue-destructive, tissue restorative, cytotoxic, migratory, bone-resorbing, pro-angiogenic, anti-angiogenic, suppressor, antigen presentation, or phagocytic. Representative diseases include atherosclerosis, arthritis, and multiple sclerosis.
    Type: Application
    Filed: December 1, 2011
    Publication date: September 6, 2012
    Applicant: APELLIS PHARMACEUTICALS, INC.
    Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson
  • Publication number: 20120214771
    Abstract: The present invention provides for methods of preventing or improving cardiometabolic disorders/metabolic disorders, compositions and pharmaceutical compositions comprising therapeutically effective amount of therapeutic phospholipid compositions and therapeutically effective amount of one or more lipid modifying agents, including statins.
    Type: Application
    Filed: November 28, 2011
    Publication date: August 23, 2012
    Inventor: Fontini Sampalis
  • Publication number: 20120141448
    Abstract: Phosphatidic acid is administered orally to increase muscle mass and strength in exercising mammals. Phosphatidic acid is administered orally to aging, bedridden or cachectic patients to improve nitrogen balance. The preferred form of phosphatidic acid for administration is phosphatidic acid-enriched lecithin. Creatine is co-administered orally to increase the muscle-building and strength effect. Other suggested additives include nutritional and herbal supplements, micronutrients and hormones.
    Type: Application
    Filed: November 23, 2011
    Publication date: June 7, 2012
    Inventors: Lorenzo De Ferra, Marvin Heuer, Scott Hagerman, Martin Purpura, Ralf Jäger
  • Publication number: 20120128762
    Abstract: The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysfunction.
    Type: Application
    Filed: January 13, 2012
    Publication date: May 24, 2012
    Inventors: Michael B. Chancellor, Pradeep Tyagi, Matthew O. Fraser, Yao-Chi Chuang, William C. de Groat, Leaf Huang, Naoki Yoshimura
  • Publication number: 20120065172
    Abstract: A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.
    Type: Application
    Filed: October 24, 2011
    Publication date: March 15, 2012
    Inventor: Fotini SAMPALIS